Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | HTR2A | P28223 | 5/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.72 |
| ▸ | HTR7 | P34969 | 4/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.72 |
| ▸ | DRD1 | P21728 | 2/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | DRD3 | P35462 | 2/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540306 | 1.00 | DRD2 (0.72) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL926016 | 0.98 | DRD2 (0.69) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL926496 | 0.92 | DRD2 (0.67) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL2541941 | 0.90 | DRD2 (0.70) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| Hydrochloric Acid SCHEMBL9594211 | 0.90 | DRD2 (0.64) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL2547414 | 0.90 | DRD2 (0.79) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL2544760 | 0.89 | DRD2 (0.77) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL2543027 | 0.87 | DRD2 (0.75) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL2547143 | 0.86 | DRD2 (0.68) | DRD2HTR2AHTR1AHTR7ADRA2C | |
| SCHEMBL2543841 | 0.86 | DRD2 (0.93) | DRD2HTR2AHTR1AHTR7ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2011-01-06 | — | — | US | disclosed |
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2011-01-06 | — | — | US | disclosed |
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | CNR2, CNR1, OPRK1 | DRD2 20/4885HTR2A 6/4885HTR1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.